The Psoriasis market growth is driven by factors like increase in the prevalence of Psoriasis, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Psoriasis market report also offers comprehensive insights into the Psoriasis market size, share, Psoriasis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Psoriasis market size growth forward.
Some of the key highlights from the Psoriasis Market Insights Report:
- Several key pharmaceutical companies, including Mylan, Biocad, Bristol-Myers Squib, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others, are developing novel products to improve the Psoriasis treatment outlook.
- The total Psoriasis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Psoriasis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Psoriasis Market Landscape
Psoriasis Overview
Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis.
It is possible to observe mild (<2%), moderate (2–10%), and severe (>10%) psoriasis in different people, however the most commonly witnessed psoriasis is chronic plaque psoriasis or psoriasis vulgaris. It is a chronic inflammatory skin disorder in which the dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes lead to skin lesions. Topical therapies are the standard of care for the treatment of mild to moderate form of the disease.
Psoriasis Types
- Plaque psoriasis
- Guttate psoriasis
- Flexural (inverse) psoriasis
- Erythroderma
- Generalised pustular psoriasis
- Palmoplantar pustulosis
- Psoriatic nail disease
Psoriasis Diagnosis
The diagnosis of psoriasis is found to be mostly on a clinical basis. The hallmarks observed in case of patients affected with psoriasis are well-demarcated, symmetric, and erythematous plaques with overlying silvery scale. Plaques can be seen typically in areas such as scalp, trunk, buttocks, and extremities but can also occur anywhere on the body. Patients can also depict nail involvement that can be present without concomitant plaques.
Psoriasis Treatment
A major population of patients can get benefitted from the topical therapies; this can also be initiated at the primary care level. If these particular topical agents do not provide an adequate response, the patients can be further referred to a dermatologist, at this particular point systemic therapy with topical adjuncts might be more beneficial. Presence of psoriatic arthritis involves systemic therapies in collaboration with a rheumatologist.
Do you know the treatment paradigms for different countries? Download our Psoriasis Market Sample Report
Recent Advancement in the Psoriasis Market
FDA Decision on Bimekizumab Approval for Psoriasis Delayed: The US Food and Drug Administration’s (FDA’s) review of the biologics license application (BLA) for bimekizumab for the treatment of psoriasis is continuing. A decision on the approval application has been delayed until the third quarter of this year, according to a June 26 announcement by the manufacturer, UCB.
Psoriasis Epidemiology Segmentation
DelveInsight’s Psoriasis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Psoriasis historical patient pools and forecasted Psoriasis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Psoriasis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Psoriasis Prevalence
- Age-Specific Psoriasis Prevalence
- Gender-Specific Psoriasis Prevalence
- Diagnosed and Treatable Cases of Psoriasis
Visit for more @ Psoriasis Epidemiological Insights
Psoriasis Treatment Market
The Psoriasis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Psoriasis market trends by analyzing the impact of current Psoriasis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Psoriasis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Psoriasis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Psoriasis market in 7MM is expected to witness a major change in the study period 2019-2032.
Psoriasis Emerging Drugs
Topical roflumilast: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis.
GSK2982772: GlaxoSmithKline
GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis.
Psoriasis Key Companies
- Mylan
- Biocad
- Bristol-Myers Squib
- Celltrion
- Coherus BioSciences
- Janssen Pharmaceuticals
- Can-Fite Biopharma
- Arcutis Biotherapeutics
- Amgen
- Iltoo Pharma
- GlaxoSmithKline
- Galectin Therapeutics
- Evelo Biosciences
- Galderma
- BioMimetix JV
- Menlo Therapeutics Inc.
- Aristea Therapeutics
- UNION Therapeutics
- MetrioPharm
- Sienna Biopharmaceuticals
For more information, visit Psoriasis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Psoriasis Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Psoriasis, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Psoriasis epidemiology in the 7MM
- Psoriasis marketed and emerging therapies
- Psoriasis companies
- Psoriasis market drivers and barriers
Key Questions Answered in the Psoriasis Market Report 2032:
- What was the Psoriasis market share distribution in 2019, and how would it appear in 2032?
- What is the total Psoriasis market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Psoriasis market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Psoriasis market projected to expand at 7MM?
Table of Contents:
1 Psoriasis Market Key Comprehensive Insights
2 Psoriasis Market Report Introduction
3 Competitive Intelligence Analysis for Psoriasis
4 Psoriasis Market Analysis Overview at a Glance
5 Executive Summary of Psoriasis
6 Psoriasis Epidemiology and Market Methodology
7 Psoriasis Epidemiology and Patient Population
8 Psoriasis Patient Journey
9 Psoriasis Treatment Algorithm, Psoriasis Current Treatment, and Medical Practices
10 Key Endpoints in Psoriasis Clinical Trials
11 Psoriasis Marketed Therapies
12 Psoriasis Emerging Therapies
13 Psoriasis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Psoriasis
16 Psoriasis Market Key Opinion Leaders Reviews
18 Psoriasis Market Drivers
19 Psoriasis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Psoriasis Epidemiology 2032
DelveInsight’s “Psoriasis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Psoriasis Pipeline 2023
“Psoriasis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psoriasis market. A detailed picture of the Psoriasis pipeline landscape is provided, which includes the disease overview and Psoriasis treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/